Magdalena Dubova

Magdalena Dubova

Auto-generated profile, based on publicly available information

Magdalena Dubova

Pathology

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2019 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
JLJerzy Lasota
Jerzy Lasota
MCMałgorzata Chłopek
Małgorzata Chłopek
JLJennifer Lamoureux
Jennifer Lamoureux
JCJason Christiansen
Jason Christiansen
AKArtur Kowalik
Artur Kowalik
MMMarkku Miettinen
Markku Miettinen
This study was undertaken to determine the frequency, and the clinicopathologic and genetic features, of colon cancers driven by neurotrophic receptor tyrosine kinase (NTRK) gene fusions. Of the 7008 tumors screened for NTRK expression using a pan-Trk antibody, 16 (0.23%) had Trk immunoreactivity. ArcherDx assay detected TPM3-NTRK1 (n=9), LMNA-NTRK1 (n=3), TPR-NTRK1 (n=2) and EML4-NTRK3 (n=1) fusion transcripts in 15 cases with sufficient RNA quality. Patients were predominantly women (median age: 63 y). The tumors involved the right (n=12) and left colon unequally and were either stage T3 (n=12) or T4. Local lymph node and distant metastases were seen at presentation in 6 and 1 patients, respectively. Lymphovascular invasion was present in all cases. Histologically, tumors showed moderate to poor (n=11) differentiation with a partly or entirely solid pattern (n=5) and mucinous component (n=10), including 1 case with sheets of signet ring cells. DNA mismatch repair–deficient phenotype was seen in 13 cases. Tumor-infiltrating CD4/CD8 lymphocytes were prominent in 9 cases. Programmed death-ligand 1 positive tumor-infiltrating immune cells and focal tumor cell positivity were seen in the majority of cases. CDX2 expression and loss of CK20 and MUC2 expression were frequent. CK7 was expressed in 5 cases. No mutations in BRAF, RAS, and PIK3CA were identified. However, other genes of the PI3K-AKT/MTOR pathway were mutated. In several cases, components of Wnt/β-catenin (APC, AMER1, CTNNB1), p53, and TGFβ (ACVR2A, TGFBR2) pathways were mutated. However, no SMAD4 mutations were found. Two tumors harbored FBXW7 tumor suppressor gene mutations. NTRK fusion tumors constitute a distinct but rare subgroup of colorectal carcinomas.

1 December 2014 in Annals of Diagnostic Pathology
Verified
Journal Article
Closed access
KPKvetoslava Peckova
Kvetoslava Peckova
TVTomas Vanecek
Tomas Vanecek
PMPetr Martinek
Petr Martinek
DSDominic Spagnolo
Dominic Spagnolo
NKNaoto Kuroda
Naoto Kuroda
Ondrej HesOndrej Hes
Ondrej Hes

1 October 2014 in Annals of Diagnostic Pathology
Verified
Journal Article
Closed access
KPKvetoslava Peckova
Kvetoslava Peckova
PGPetr Grossmann
Petr Grossmann
SBStela Bulimbasic
Stela Bulimbasic
MSMaris Sperga
Maris Sperga
DMDelia Perez Montiel
Delia Perez Montiel
Ondrej HesOndrej Hes
Ondrej Hes

3 July 2020 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
JLJerzy Lasota
Jerzy Lasota
MCMałgorzata Chłopek
Małgorzata Chłopek
BWBartosz Wasag
Bartosz Wasag
AKArtur Kowalik
Artur Kowalik
JCJason Christiansen
Jason Christiansen
MMMarkku Miettinen
Markku Miettinen
This study determined the frequency and the clinicopathologic and genetic features of colorectal carcinomas driven by oncogenic fusions of the anaplastic lymphoma kinase gene (ALK). Of the 8150 screened tumors, 12 (0.15%) were immunohistochemically ALK-positive with D5F3 antibody. These cancers harbored CAD-ALK (n=1), DIAPH2-ALK (n=2), EML4-ALK (n=2), LOC101929227-ALK (n=1), SLMAP-ALK (n=1), SPTBN1-ALK (n=4), and STRN-ALK (n=1) fusions, as detected by an RNA-based next-generation sequencing assay. ALK fusion carcinomas were diagnosed mostly in older patients with a 9:3 female predominance (median age: 72 y). All tumors, except a rectal one, occurred in the right colon. Most tumors were stage T3 (n=7) or T4 (n=3). Local lymph node and distant metastases were seen at presentation in 9 and 2 patients. These tumors showed moderate (n=6) or poor (n=3) glandular differentiation, solid medullary growth pattern (n=2), and pure mucinous morphology (n=1). DNA mismatch repair–deficient phenotype was identified in 10 cases. Tumor-infiltrating lymphocytes were prominent in 9 carcinomas. In 4 carcinomas, tumor cells showed strong, focal (n=3), or diffuse programmed death-ligand 1 immunoreactivity. CDX2 expression and loss of CK20 and MUC2 expression were frequent. CK7 was expressed in 5 tumors. Four patients died of disease within 3 years, and 7 were alive with follow-up ranging from 1 to 8 years. No mutations in BRAF, RAS, and in genes encoding components of PI3K-AKT/MTOR pathway were identified. However, 1 tumor had a loss-of-function PTEN mutation. Aberration of p53 signaling, TP53 mutations, and/or nuclear accumulation of p53 protein was seen in 9 cases. ALK fusion colorectal carcinomas are a distinct and rare subtype of colorectal cancers displaying some features of mismatch repair–deficient tumors.

28 December 2014 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
MHMalcolm Hayes
Malcolm Hayes
KPKvetoslava Peckova
Kvetoslava Peckova
PMPetr Martinek
Petr Martinek
MHMilan Hora
Milan Hora
KKKristyna Kalusova
Kristyna Kalusova
Ondrej HesOndrej Hes
Ondrej Hes

1 August 2015 in Annals of Diagnostic Pathology
Verified
Journal Article
Closed access
KPKvetoslava Peckova
Kvetoslava Peckova
PMPetr Martinek
Petr Martinek
MSMaris Sperga
Maris Sperga
DMDelia Perez Montiel
Delia Perez Montiel
ODOndrej Daum
Ondrej Daum
Ondrej HesOndrej Hes
Ondrej Hes